Alisol B 23-acetate

Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma[1][2][3][4][5][6][7][8][9][10][11][12][13][14].

Product Specifications

CAS Number

[26575-95-1]

Product Name Alternative

23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; CDK; FXR; MMP; PARP; Reactive Oxygen Species (ROS) ; Syk

Type

Natural Products

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Alisol-B-23-acetate.html

Purity

99.65

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

C[C@]([C@@]1(C2=C([C@H](C)C[C@@H]([C@]3([H])C(C)(C)O3)OC(C)=O)CC1)C)(CC[C@@]4([H])C5(C)C)[C@]([C@H](C2)O)([H])[C@]4(CCC5=O)C

Molecular Formula

C32H50O5

Molecular Weight

514.74

Precautions

H302

References & Citations

[1]Zhang LL, et al. Effects of alisol B 23-acetate on ovarian cancer cells: G1 phase cell cycle arrest, apoptosis, migration and invasion inhibition. Phytomedicine. 2016 Jul 15;23 (8) :800-9.|[2]Wang C, et al. Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. Biochem Pharmacol. 2004 Sep 1;68 (5) :843-55. |[3]Zhao Y, et al.Alisol B 23-acetate induces autophagic-dependent apoptosis in human colon cancer cells via ROS generation and JNK activation. Oncotarget. 2017 Jul 26;8 (41) :70239-70249. |[4]Wang J, et al. Alisol B-23-acetate, a tetracyclic triterpenoid isolated from Alisma orientale, induces apoptosis in human lung cancer cells via the mitochondrial pathway. Biochem Biophys Res Commun. 2018 Nov 10;505 (4) :1015-1021.|[5]Fu Y, et al. Alisol B 23-acetate adjusts bile acid metabolisim via hepatic FXR-BSEP signaling activation to alleviate atherosclerosis. Phytomedicine. 2022 Jul;101:154120.|[6]Kwon MJ, et al. Apoptotic effects of alisol B 23‑acetate on gastric cancer cells. Mol Med Rep. 2021 Apr;23 (4) :248. |[7]Shao C, et al. Alisol B 23-Acetate Inhibits IgE/Ag-Mediated Mast Cell Activation and Allergic Reaction. Int J Mol Sci. 2018 Dec 18;19 (12) :4092.|[8]Sun Y, et al. Alisol B 23-acetate, a new promoter for cholesterol efflux from dendritic cells, alleviates dyslipidemia and inflammation in advanced atherosclerotic mice. Int Immunopharmacol. 2021 Oct;99:107956.|[9]Wang B, et al. Alisol B 23-Acetate Ameliorates Lipopolysaccharide-Induced Cardiac Dysfunction by Suppressing Toll-Like Receptor 4 (TLR4) /NADPH Oxidase 2 (NOX2) Signaling Pathway. Med Sci Monit. 2019 Nov 10;25:8472-8481.|[10]Meng Q, et al. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation. Acta Pharmacol Sin. 2017 Jan;38 (1) :69-79. |[11]Meng Q, et al. Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor. Biochem Pharmacol. 2014 Nov 15;92 (2) :289-98.|[12]Meng Q, et al. Protective effects of alisol B 23-acetate from edible botanical Rhizoma alismatis against carbon tetrachloride-induced hepatotoxicity in mice. Food Funct. 2015 Apr;6 (4) :1241-50. |[13]Luan ZL, et al. A naturally occurring FXR agonist, alisol B 23-acetate, protects against renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2021 Nov 1;321 (5) :F617-F628. |[14]Nam KH, et al. Alisol B 23-Acetate Ameliorates Ovalbumin-Induced Allergic Asthma during Sensitization and Challenge Periods. Biomol Ther (Seoul) . 2023 Nov 1;31 (6) :611-618.